News ADA: AZ reveals oral GLP-1 data in obesity, diabetes AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.
News AstraZeneca raises guidance on stellar cancer drugs growth AZ reports strong financial results for 2025, and provides a first peek at the data for its oral GLP-1 contender elecoglipron.
News Lilly's BTK drug Jaypirca joins first-line options in US Lilly's noncovalent BTK inhibitor Jaypirca has been cleared by the FDA for its first frontline indication, but will it be reserved for later-line use?
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.